2026 Global: Antibody Fragments-Competitive Review (2032) report
Description
The 2026 Global: Antibody Fragments-Competitive Review (2031) report features the global market size and projected growth/decline data for the period 2021 through 2032. The report primarily provides an examination of the business strategies for the ten largest global companies in the market and how their strategies differ.
Perry/Hope Partners' reports provide the most accurate industry forecasts based on our proprietary economic models. Our forecasts project the product market size nationally and by regions for 2021 to 2032 using regression analysis in our modeling. and Perry/Hope is the only market research publisher that utilizes both longitudinal (historical) and vertical (from market section to market division to market class) analysis, since we study every manufactured product in the countries we analyze. The report also provides written analysis on the market definition, market segments, and SWOT analysis (market strengths, weaknesses, opportunities, and threats).
The market study aims at estimating the market size and the growth potential of this market. Topics analyzed within the report include a detailed breakdown of the global markets for antibody fragments by geography and historical trend. The scope of the report extends to sizing of the antibody fragments market and global market trends with market data for 2024 as the base year, 2025 and 2026 as the estimate years with projection of CAGR from 2027 to 2032.
The report also features a list of the top ten largest global players in the market. A review of each company includes 1) an estimate of the market share, 2) a listing of the products and/or services in the market, and 3) the features of these products and/or services in the market. The report has a chapter on Comparative Business Strategies for the largest four players. An example of the Comparative Business Strategies analysis would be -- How does Netflix's business strategy to expand its market share in the global online streaming compare to Amazon Prime's business strategy through its video products and services?
The ten market players in this report and a brief synopsis of their participation in the market are:
Roche, Novartis, Amgen, Pfizer, and Johnson & Johnson are among the leading companies driving innovation in antibody fragments, each leveraging established biologics capabilities and expanding fragment-specific platforms to address oncology, immunology, and rare diseases. F. Hoffmann‑La Roche (including Genentech) has a strong footprint in Fab and bispecific fragment therapeutics and diagnostics, advancing fragment-based oncology candidates and scalable production technologies as part of its broader antibody portfolio. Novartis has made sizable strategic investments and acquisitions to build next‑generation fragment and bispecific platforms for solid tumors and orphan indications, positioning itself as a major fragment developer in oncology and immunology. Amgen emphasizes engineered single‑chain variable fragments (scFv) and recombinant fragment platforms for immunotherapy applications, leveraging its recombinant biologics expertise and partnerships to mature fragment candidates. Pfizer pursues fragment and antibody engineering programs across cancer and infectious disease spaces, integrating global development and manufacturing scale to move fragment-derived candidates through clinical stages. Johnson & Johnson applies its broad life‑science capabilities to develop fragment modalities for autoimmune and inflammatory diseases, expanding pipelines and clinical programs in fragment-based formats.
AbbVie, Bristol‑Myers Squibb, Sanofi, Takeda, and Biogen represent established pharma and biotech leaders that contribute significant clinical pipelines, manufacturing capacity, and fragment‑centric research collaborations to the antibody‑fragment landscape. AbbVie invests in high‑affinity fragment formats and has broadened antibody research capabilities through acquisitions and partnerships aimed at immunology and oncology indications. Bristol‑Myers Squibb focuses on fragment and blocking antibody technologies for oncology and immune modulation, supporting rapid clinical translation through advanced screening and optimization approaches. Sanofi develops bispecific and next‑generation fragment constructs for complex disease pathways and leverages an extensive global R&D network to advance fragment candidates toward commercialization. Takeda integrates fragment science into its biologics pipeline, particularly for immunology and rare disease programs, while partnering with specialized biotech firms to access novel fragment platforms. Biogen applies fragment and engineered antibody approaches in neurology and immunology research, contributing targeted fragment candidates and collaborations that address central nervous system and inflammatory disorders.
Smaller specialist players, CMOs, and biotech innovators complement the major companies by offering proprietary fragment platforms, nanobody expertise, and dedicated manufacturing services that accelerate development and scale-up. Companies such as WuXi Biologics, Samsung BioLogics, Lonza and dedicated fragment-focused biotechs supply contract development and high‑yield expression systems that many large firms utilize to produce Fab, scFv, and nanobody constructs at commercial scale. Nanobody developers and niche fragment companies have catalyzed growth by exploiting compact single‑domain scaffolds for difficult targets and enabling lower‑cost bacterial expression routes, which has increased investment and M&A activity across the sector. Market research consistently ranks Roche, Novartis, Amgen, Pfizer, J&J, AbbVie, BMS, Sanofi, Takeda and Biogen among the top players in antibody fragments based on pipeline activity, strategic deals, and manufacturing footprints that together shape the competitive landscape for fragment therapeutics and diagnostics.
Perry/Hope Partners' reports provide the most accurate industry forecasts based on our proprietary economic models. Our forecasts project the product market size nationally and by regions for 2021 to 2032 using regression analysis in our modeling. and Perry/Hope is the only market research publisher that utilizes both longitudinal (historical) and vertical (from market section to market division to market class) analysis, since we study every manufactured product in the countries we analyze. The report also provides written analysis on the market definition, market segments, and SWOT analysis (market strengths, weaknesses, opportunities, and threats).
The market study aims at estimating the market size and the growth potential of this market. Topics analyzed within the report include a detailed breakdown of the global markets for antibody fragments by geography and historical trend. The scope of the report extends to sizing of the antibody fragments market and global market trends with market data for 2024 as the base year, 2025 and 2026 as the estimate years with projection of CAGR from 2027 to 2032.
The report also features a list of the top ten largest global players in the market. A review of each company includes 1) an estimate of the market share, 2) a listing of the products and/or services in the market, and 3) the features of these products and/or services in the market. The report has a chapter on Comparative Business Strategies for the largest four players. An example of the Comparative Business Strategies analysis would be -- How does Netflix's business strategy to expand its market share in the global online streaming compare to Amazon Prime's business strategy through its video products and services?
The ten market players in this report and a brief synopsis of their participation in the market are:
Roche, Novartis, Amgen, Pfizer, and Johnson & Johnson are among the leading companies driving innovation in antibody fragments, each leveraging established biologics capabilities and expanding fragment-specific platforms to address oncology, immunology, and rare diseases. F. Hoffmann‑La Roche (including Genentech) has a strong footprint in Fab and bispecific fragment therapeutics and diagnostics, advancing fragment-based oncology candidates and scalable production technologies as part of its broader antibody portfolio. Novartis has made sizable strategic investments and acquisitions to build next‑generation fragment and bispecific platforms for solid tumors and orphan indications, positioning itself as a major fragment developer in oncology and immunology. Amgen emphasizes engineered single‑chain variable fragments (scFv) and recombinant fragment platforms for immunotherapy applications, leveraging its recombinant biologics expertise and partnerships to mature fragment candidates. Pfizer pursues fragment and antibody engineering programs across cancer and infectious disease spaces, integrating global development and manufacturing scale to move fragment-derived candidates through clinical stages. Johnson & Johnson applies its broad life‑science capabilities to develop fragment modalities for autoimmune and inflammatory diseases, expanding pipelines and clinical programs in fragment-based formats.
AbbVie, Bristol‑Myers Squibb, Sanofi, Takeda, and Biogen represent established pharma and biotech leaders that contribute significant clinical pipelines, manufacturing capacity, and fragment‑centric research collaborations to the antibody‑fragment landscape. AbbVie invests in high‑affinity fragment formats and has broadened antibody research capabilities through acquisitions and partnerships aimed at immunology and oncology indications. Bristol‑Myers Squibb focuses on fragment and blocking antibody technologies for oncology and immune modulation, supporting rapid clinical translation through advanced screening and optimization approaches. Sanofi develops bispecific and next‑generation fragment constructs for complex disease pathways and leverages an extensive global R&D network to advance fragment candidates toward commercialization. Takeda integrates fragment science into its biologics pipeline, particularly for immunology and rare disease programs, while partnering with specialized biotech firms to access novel fragment platforms. Biogen applies fragment and engineered antibody approaches in neurology and immunology research, contributing targeted fragment candidates and collaborations that address central nervous system and inflammatory disorders.
Smaller specialist players, CMOs, and biotech innovators complement the major companies by offering proprietary fragment platforms, nanobody expertise, and dedicated manufacturing services that accelerate development and scale-up. Companies such as WuXi Biologics, Samsung BioLogics, Lonza and dedicated fragment-focused biotechs supply contract development and high‑yield expression systems that many large firms utilize to produce Fab, scFv, and nanobody constructs at commercial scale. Nanobody developers and niche fragment companies have catalyzed growth by exploiting compact single‑domain scaffolds for difficult targets and enabling lower‑cost bacterial expression routes, which has increased investment and M&A activity across the sector. Market research consistently ranks Roche, Novartis, Amgen, Pfizer, J&J, AbbVie, BMS, Sanofi, Takeda and Biogen among the top players in antibody fragments based on pipeline activity, strategic deals, and manufacturing footprints that together shape the competitive landscape for fragment therapeutics and diagnostics.
Table of Contents
32 Pages
- 1.0 Scope of Report and Methodology
- 2.0 Market SWOT Analysis and Players
- 2.1 Market Definition
- 2.2 Market Segments
- 2.3 Market Strengths
- 2.4 Market Weaknesses
- 2.5 Market Threats
- 2.6 Market Opportunities
- 2.7 Major Players
- 3.0 Competitive Analysis
- 3.1 Market Player 1
- 3.2 Market Player 2
- 3.3 Market Player 3
- 3.4 Market Player 4
- 3.5 Market Player 5
- 3.6 Market Player 6
- 3.7 Market Player 7
- 3.8 Market Player 8
- 3.9 Market Player 9
- 3.10 Market Player 10
- 4.0 Comparative Business Strategies
- 4.1 Comparative Business Strategies of Player 1 and 2
- 4.2 Comparative Business Strategies of Player 1 and 3
- 4.3 Comparative Business Strategies of Player 1 and 4
- 4.4 Comparative Business Strategies of Player 2 and 3
- 4.5 Comparative Business Strategies of Player 2 and 4
- 4.6 Comparative Business Strategies of Player 3 and 4
- 5.0 Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
